MarketScreener Homepage > Equities > Korea Stock Exchange > SAMSUNG PHARM. Co., LTD. A001360 KR7001360007

Report

End-of-day quote Korea Stock Exchange - 12/04
3735	KRW		-2.35%

Summary

Quotes 5-day view End-of-day quote.

End-of-day quote Korea Stock Exchange

11/30/2020	12/01/2020	12/02/2020	12/03/2020	12/04/2020	Date
3865	3835	3870	3825	3735	Last
1012119	604646	859116	555107	935354	Volume
+2.11%	-0.78%	+0.91%	-1.16%	-2.35%	Change

Financials

Sales 2017	41 919 M 38,7 M 38,7 M
Net income 2017	-7 540 M -6,96 M -6,96 M
Net Debt 2017	18 710 M 17,3 M 17,3 M
P/E ratio 2017	-21,3x
Yield 2017	-

Sales 2018	46 484 M 42,9 M 42,9 M
Net income 2018	-2 076 M -1,92 M -1,92 M
Net cash position 2018	14 955 M 13,8 M 13,8 M
P/E ratio 2018	-62,5x
Yield 2018	-

Capitalization	230 B 212 M 212 M
EV / Sales 2017	4,42x
EV / Sales 2018	2,85x
Nbr of Employees	240
Free-Float	83,5%

More Financials

Company

SAMSUNG PHARM. Co., LTD., formerly SAMSUNG PHARMACEUTICAL.CO.,Ltd., is a Korea-based company engaged in the manufacturing and distributing of pharmaceutical products. The Company provides over the counter (OTC) pharmaceuticals, prescription pharmaceuticals, healthcare food, healthcare drinks, insecticides and others. The pharmaceutical products consist of gastrointestinal drugs, antipyretics, analgesics and...

Sector

Pharmaceuticals

Calendar

04/05

Earnings Release

More about the company

All news about SAMSUNG PHARM. CO., LTD.

- No features available -

More news

News in other languages on SAMSUNG PHARM. CO., LTD.

- No features available -

More news

Provided by Scoopnest.com

Chart SAMSUNG PHARM. CO., LTD.

Duration : Period :

SAMSUNG PHARM. Co., LTD. Technical Analysis Chart | MarketScreener

Full-screen chart

Technical analysis trends SAMSUNG PHARM. CO., LTD.

	Short Term	Mid-Term	Long Term
Trends	Bullish	Bearish	Neutral

Technical analysis

Income Statement Evolution

More Financials

Managers

Name	Title
Sang-Jae Kim	Co-Chief Executive Officer & Director
Ki-Ho Kim	Co-Chief Executive Officer & Director
Byung-Won Jang	Director
Woo-Jin Kim	Independent Director
Gi-Woong Kim	Director

More about the company

Sector and Competitors

	1st jan.	Capitalization (M$)

SAMSUNG PHARM. CO., LTD.	-10.97%	212



OTSUKA HOLDINGS CO., LTD.	-10.55%	22 735
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO., LTD.	107.86%	19 536
SUN PHARMACEUTICAL INDUSTRIES LTD.	31.56%	18 509
ONO PHARMACEUTICAL CO., LTD.	30.30%	15 617
DIVI'S LABORATORIES LIMITED	101.10%	13 358

More Results